Peptide Experts Worth Following

Dr. Peter Attia is a Stanford- and Johns Hopkins-trained physician who practices longevity medicine and has written extensively on metabolic health, hormones, and pharmaceutical interventions including peptides. His podcast 'The Drive' features some of the most scientifically rigorous discussions of peptide therapy, GLP-1 pharmacology, and growth hormone optimization available to the public.

Dr. Andrew Huberman is a tenured professor of neurobiology and ophthalmology at Stanford School of Medicine. His Huberman Lab podcast has featured comprehensive deep-dives into peptides including BPC-157, growth hormone secretagogues, and GLP-1 agonists, drawing directly from peer-reviewed literature. He is known for his ability to explain complex neuroscience and endocrinology mechanisms to broad audiences.

Dr. Rand McClain is a board-certified physician specializing in sports medicine and regenerative therapies. He has worked extensively with peptide protocols for athletic recovery, anti-aging, and hormonal optimization. McClain has been a clinical voice for applying peptide research practically, bridging the gap between animal study data and real-world clinical use in patients.

Dr. Kyle Gillett is a family medicine and obesity medicine physician with a subspecialty focus on hormone optimization and metabolic health. He has become a prominent voice in evidence-based peptide and hormone therapy, regularly discussing the clinical applications of GLP-1 agonists, growth hormone secretagogues, and peptides like BPC-157 in the context of patient care. He is known for nuanced, balanced takes that integrate scientific evidence with practical clinical wisdom.

Dr. Abud Bakri is a board-certified internal medicine physician who runs a peptide-focused clinical practice. He was the featured guest on the Huberman Lab episode 'Peptides: The Science, Uses & Safety' (2026), a roughly three-hour deep dive spanning BPC-157, GHK-Cu, pinealon/epithalon, GLP-1 agonists, and growth-hormone peptides. He is notable for an evidence-honest framing, openly emphasizing that most mechanistic data for popular research peptides comes from animal and in-vitro studies with few well-controlled human trials, and for his focus on sourcing safety and responsible clinical use.

Dr. Predrag Šikirić is the Croatian scientist who pioneered BPC-157 research beginning in the early 1990s. He is the principal author of dozens of peer-reviewed studies on BPC-157's effects on gastrointestinal healing, tendon repair, neurological protection, and systemic organ defense. While primarily an academic researcher rather than a public educator, his body of work is foundational to everything the research peptide community knows about BPC-157.

Dr. Changhan David Lee is the scientist who discovered MOTS-c in 2015, publishing the foundational work in Cell Metabolism. At USC's Leonard Davis School of Gerontology, he leads research on mitochondrial-derived peptides, a novel class of signaling molecules encoded within mitochondrial DNA, and their role in metabolic regulation, exercise response, insulin sensitivity, and aging. Primarily an academic researcher rather than a public educator, his lab's work underpins essentially everything known about MOTS-c and the emerging mitochondrial-peptide field. His work is especially timely with MOTS-c up for FDA Pharmacy Compounding Advisory Committee review in July 2026.

Dr. William Seeds is a board-certified orthopaedic surgeon and the founder and academic chairman of the Seeds Scientific Research & Performance (SSRP) Institute, where he trains physicians in clinical peptide therapy and cellular medicine. He authored the influential 'Peptide Protocols, Volume One', one of the first practical clinical references for prescribing peptides, and has spent four decades bridging surgical practice, research, and physician education. His work focuses on the cellular and epigenetic mechanisms underlying peptide signaling.

Dr. Edwin Lee is a board-certified endocrinologist (Internal Medicine, Endocrinology, Diabetes & Metabolism) who founded the Institute for Hormonal Balance in Orlando in 2008 and serves as an assistant professor of Internal Medicine at the University of Central Florida College of Medicine. A co-founder of the Clinical Peptide Society and author of 'The Fountain of Youth with Peptides,' he lectures internationally on peptide therapy and has been a prominent clinical voice in the 2026 policy debate over preserving access to compounded peptides.

Dr. Craig Koniver, trained at Brown University and Jefferson Medical College, is a performance-medicine physician who has used peptides, NAD+, and bioidentical hormones in clinical practice for nearly two decades. He founded Koniver Wellness and the Koniver Method, a certification program teaching clinicians evidence-informed peptide and IV protocols. He is known to wider audiences for his detailed, mechanism-focused discussion of peptide and hormone therapies on the Huberman Lab podcast.

Dr. Neil Paulvin is a New York City-based osteopathic physician with 20+ years in practice and board certifications spanning Family Medicine, Osteopathic Manipulative Medicine, Anti-Aging/Regenerative Medicine (A4M), and Holistic/Integrative Medicine, with additional certification from the Institute for Functional Medicine. He runs an active clinical peptide program that includes BPC-157, TB-500, Epitalon, and other longevity-relevant peptides, and he is a recurring guest on biohacking and longevity podcasts where he discusses the practical clinical application of these compounds. His integrative background gives him a broader lens than most peptide clinicians, combining functional medicine diagnostics, osteopathic structural assessment, and evidence-informed peptide protocols for his patients.

Nathalie Niddam is a certified holistic nutritionist and epigenetics coach who hosts the LONGEVITY Podcast, one of the more substantive independent shows covering peptides, bioregulators, and healthspan science. While not a physician, she is a careful, citation-driven educator who interviews clinicians and researchers and is widely credited with making the science of bioregulator peptides accessible to a general audience without overselling it.

Dr. Lee Kaplan is a physician-scientist who directs the Obesity, Metabolism & Nutrition Institute at Massachusetts General Hospital and serves as an associate professor of medicine at Harvard Medical School. A leading authority on the biology of obesity and metabolic disease, he chairs the phase 3 SYNCHRONIZE program studying survodutide and is a co-author of pivotal New England Journal of Medicine data on dual GLP-1/glucagon receptor agonists for obesity. He is an active clinical-science voice at ADA 2026, emphasizing the metabolic benefits of incretin-based peptide drugs, such as visceral and liver-fat reduction, beyond simple scale weight.